JPS5886087A - Novel antibiotic substance sf-2132 and its preparation - Google Patents
Novel antibiotic substance sf-2132 and its preparationInfo
- Publication number
- JPS5886087A JPS5886087A JP56184643A JP18464381A JPS5886087A JP S5886087 A JPS5886087 A JP S5886087A JP 56184643 A JP56184643 A JP 56184643A JP 18464381 A JP18464381 A JP 18464381A JP S5886087 A JPS5886087 A JP S5886087A
- Authority
- JP
- Japan
- Prior art keywords
- water
- antibiotic
- substance
- manufactured
- acetic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
Description
【発明の詳細な説明】
本発明は新抗生物質及びその製造法に関するものであり
、さらに詳しくは抗生物質5F−2132及びノカルデ
ィオプシス(Nocar−diopsis)属に属する
5F−2132物質生産菌を培地に培養し、得られた培
養物から抗生物質5F−2132を採取することを特徴
とする新抗生物質5F−2132の製造法に関するもの
である。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a new antibiotic and a method for producing the same, and more specifically, the present invention relates to a new antibiotic and a method for producing the same. The present invention relates to a method for producing a new antibiotic 5F-2132, which is characterized by culturing the antibiotic 5F-2132 and collecting the antibiotic 5F-2132 from the obtained culture.
本発明者らは、ある種の菌株の培養物中に細菌に対して
抗菌作用を示す物質が生産されていることを見出し、そ
の有効物質を培養物から純粋に単離し、その性状を調べ
た結果、既知の物質とは興なる新抗生物質であることを
確認し、この有効物質を抗生物質5F−2132と命名
した。The present inventors discovered that a substance that exhibits an antibacterial effect against bacteria is produced in the culture of a certain bacterial strain, isolated the effective substance from the culture, and investigated its properties. As a result, it was confirmed that the known substance was a new antibiotic, and this effective substance was named antibiotic 5F-2132.
本発明の抗生物質5F−2132生産菌としては、その
培養物中に、採取するに充分な量の抗生物質5F−21
32を生産する能力を有するものであれば、いかなるも
のであってもよいが、このような菌株の一例としては、
本発明者らにより、奈良県橿原市の土壌より新たに分離
された5F−2132株がある。該菌株の菌学的性状は
下記の通りである。The antibiotic 5F-2132-producing bacteria of the present invention contains a sufficient amount of antibiotic 5F-21 in its culture to be collected.
Any strain may be used as long as it has the ability to produce 32, but an example of such a strain is
There is a strain 5F-2132 newly isolated by the present inventors from the soil of Kashihara City, Nara Prefecture. The mycological properties of this strain are as follows.
なお、観察は主に5HIRLING、E、B。In addition, observation is mainly 5HIRLING, E, and B.
とGOTTLIEB、D、により
International Journalof
SystmatLc BacLeriol。and GOTTLIEB, D., International Journal of
SystmatLc BacLeriol.
16、 313−340 (1966)に記載されてい
る方法に従って、行った。16, 313-340 (1966).
■ 形態
基体菌糸は直径0.4〜0.6ミクロンで寒天培地にお
いては単純分枝して波状に伸長するが、液体培地におい
ては培養に従って不規則に分断する。(2) Morphology Substrate hyphae have a diameter of 0.4 to 0.6 microns, and in agar media, they simply branch and elongate in a wavy manner, but in liquid media, they divide irregularly as they are cultured.
気菌糸は直径0.4〜0.6ミクロンで豊富に形成され
、単純分枝し菌糸全体が胞子の連鎖となる。胞子は通常
10胞子以上連鎖する。胞子は卵型〜円筒型で大きさは
1.0〜1.5X0.4〜0.6ミクロン、表面は平滑
で運動性は認められなかった。その他胞子のう、鞭毛胞
子、菌核等の特殊構造は認められなかった。Aerial hyphae are abundantly formed with a diameter of 0.4 to 0.6 microns, and are simply branched, with the entire hyphae becoming a chain of spores. Spores usually form chains of 10 or more spores. The spores were oval to cylindrical in size, 1.0 to 1.5 x 0.4 to 0.6 microns, had a smooth surface, and no motility was observed. Other special structures such as sporangia, flagellated spores, and sclerotia were not observed.
■ 各種培地上の生育状態
5F1132株の各種培地上の生育状態は次表に示す通
りである。色の記載について〔〕内に示す標準はコンテ
ナー・コーポレーシ霞ン・オプ・アメリカ (Cont
ainer Corporationgy、of
America)社製の[カラー・ハーモニー・?二、
フル(Color HarmonyManual)J
に記載のものを用いな。観察は28℃で、14〜21日
培養後に行った。■ Growth status on various media The growth status of the 5F1132 strain on various media is shown in the following table. Regarding the description of colors, the standards shown in [ ] are those of Container Corporation Kasumi Op America (Cont.
ainer Corporation, of
America) [Color Harmony? two,
Full (Color Harmony Manual) J
Use the one listed in. Observation was performed at 28° C. after 14 to 21 days of culture.
■ 生理的性質
il+ 生育温度範囲:スターチ寒天において15〜
40℃の温度範囲で生育し、25〜37℃で良好に生育
する。■ Physiological properties IL+ Growth temperature range: 15 to 15% on starch agar
It grows in a temperature range of 40°C and grows well at 25-37°C.
(2)ゼラチンの液化:陽性
(3) スターチの加水分解:陰性
(4) 硝酸塩の還元:陰性
(5) 脱脂乳の凝固:陽性
脱脂乳のペプトン化:陽性
(6) メラニン様色素の生成:陽性(7)耐塩性ニ
ア、0%ではわずかに生育するが1080%以上では生
育しない。(2) Liquefaction of gelatin: Positive (3) Hydrolysis of starch: Negative (4) Reduction of nitrate: Negative (5) Coagulation of skim milk: Positive Peptonization of skim milk: Positive (6) Production of melanin-like pigments: Positive (7) Near salt tolerance, grows slightly at 0% but does not grow at 1080% or higher.
■ 炭素源の利用性
炭素源 生育
D−グルコース ++
D−キシロース ++
D−フラクトース ++
D−マンニトール +
L−アラビノース ++
L−ラムノース +
i−イノシトール +
シュクロース ++
ラフィノース +
無添加 士
十十 良好1こ生育(利用性二十)
十 弱い生育(利用性ニー)
用いた基本培地
酵母エキス(Difco社製)5g
炭酸カルシウム 1g
寒天(Difco社製)15g
蒸留水 10100O!■ 細胞壁
組成
全細胞加水分解物中のジアミノピメリン酸は主にメン型
で、キシロース、マジニロース、アラビノースは認めら
れなかった。■ Utilization of carbon source Carbon source Growth D-glucose ++ D-xylose ++ D-fructose ++ D-mannitol + L-arabinose ++ L-rhamnose + i-inositol + sucrose ++ Raffinose + No additives Growth (Usability 20) 10 Weak Growth (Usability Knee) Basic medium used Yeast extract (manufactured by Difco) 5g Calcium carbonate 1g Agar (manufactured by Difco) 15g Distilled water 10100O! ■ Cell wall composition Diaminopimelic acid in the whole cell hydrolyzate was mainly of men type, and xylose, madinylose, and arabinose were not observed.
以上の諸性状を総合し、基体菌糸が分断し、気菌糸全体
が胞子の連鎖を形成する形態的な特徴を有し、かつ全細
胞加水分解物中にメン型のジアミノヒメリン酸を持ち、
キシロース、マジ二ロース。Combining the above properties, the substrate hyphae are divided, the entire aerial hyphae has the morphological characteristics of forming a chain of spores, and the whole cell hydrolyzate contains men-type diaminohimelic acid.
Xylose, Majinylose.
アラビノースを持たないものは放線菌の中でノカルディ
オプシス(Nocardiopsis)属に属する。(
InternationalJournal of
SystematicBac ter i o Io
gy、 26. 487〜493.1976)従って、
本発明者等は5F−2132株をノカルディオプシス・
エスピー・5F−2132(Nocardiopsis
sp、5F−2132)と命名した。5F−213
2株は、微生物工業技術研究所に機工研菌寄第6131
号として受託されている。Those that do not have arabinose belong to the genus Nocardiopsis among actinomycetes. (
International Journal of
Systematic Bac ter i o Io
gy, 26. 487-493.1976) Therefore,
The present inventors used strain 5F-2132 as Nocardiopsis.
SP・5F-2132 (Nocardiopsis
sp, 5F-2132). 5F-213
The two strains were transferred to the Microbial Technology Research Institute, Kikoken Bacteria Collection No. 6131.
It has been entrusted as the No.
本発明は、上記の知見に基いて完成されたもので、ノカ
ルディオプシス属に属する抗生物質SF−2132生産
菌を培養し、その培養物より抗生物質5F−2132を
採取することを特徴とする抗生物質5F−2132の製
造法並びに耐抗生物質5F−2132である。The present invention was completed based on the above findings, and is characterized by culturing antibiotic SF-2132-producing bacteria belonging to the genus Nocardiopsis, and collecting antibiotic 5F-2132 from the culture. A method for producing antibiotic 5F-2132 and antibiotic-resistant 5F-2132.
ノカルディオプシス・エスピー・5F2132Nは他の
放線菌の場合にみられるように、その性状が変化しやす
く、例えば、紫外線、エックス線、放射線、薬品等を用
いる人工的変興牟段で変興しうるものであり、このよう
な変異株であっても抗生物質5F−2132の生産能を
有するノカルディオプシス属の菌はすべて本発明の方法
に使用することができる。Nocardiopsis sp. 5F2132N is susceptible to changes in its properties, as seen in the case of other actinomycetes, and can be transformed by artificial transformation using ultraviolet rays, X-rays, radiation, chemicals, etc. Therefore, all Nocardiopsis bacteria capable of producing the antibiotic 5F-2132, even such mutant strains, can be used in the method of the present invention.
本発明の方法では、5F−2132株を通常、微生物が
利用しうる栄養物を含有する培地で培養する。In the method of the present invention, strain 5F-2132 is typically cultured in a medium containing nutrients that can be utilized by the microorganism.
例えば、炭素源としてグルコース、シュクロース、デキ
ストリン、殿粉、水あめ、糖みっ、大豆油等を使用しう
み。For example, seaweed using glucose, sucrose, dextrin, starch, starch syrup, sugar syrup, soybean oil, etc. as a carbon source.
又窒素源として大豆粉、小麦胚芽、ペプトン。Soy flour, wheat germ, and peptone are also used as nitrogen sources.
肉エキス、酵母エキス、コーンステイープリカー。Meat extract, yeast extract, cornstarch liquor.
硝酸ソーダ、硫酸アンモニウム等を使用しうる。Sodium nitrate, ammonium sulfate, etc. can be used.
ソノ他、必要に応じて炭酸カルシウム、塩化カリウム、
燐酸塩等の無機塩類を添加するほか菌の発育を助け、抗
生物質5F−2132(以後、5F−2132物質と称
する)の生産を促進するごとき有機物及び無機物を適当
に添加することができる。Calcium carbonate, potassium chloride, etc. as necessary
In addition to adding inorganic salts such as phosphates, organic and inorganic substances that aid the growth of bacteria and promote the production of antibiotic 5F-2132 (hereinafter referred to as 5F-2132 substance) can be appropriately added.
培養法としては、一般抗生物質生産の方法と同じく、好
気的条件下での培養法であれば、いがなる方法を適用し
てもよいが、P4部培養法が量も適している。培養に適
した温度は20〜35℃であるが、多くの場合部〜羽℃
付近で培養を行うのが好ましい。5F−2132物質の
生産は振盪培養法、タンク培養法共に2〜7日で蓄積が
最高に達する。As a culture method, the burr method may be applied as long as it is a culture method under aerobic conditions, similar to the method for general antibiotic production, but the P4 culture method is suitable in terms of quantity. The suitable temperature for culturing is 20-35℃, but in many cases it is
It is preferable to culture in the vicinity. The production of 5F-2132 substance reaches its maximum accumulation in 2 to 7 days in both the shaking culture method and the tank culture method.
5F−2132物質の検定に当っては、スタヒロコソカ
ス・アウレウス(Staphylococcusaur
eus)209pを検定菌とするペーノマーディスク・
平板法を用いる。この検定法では、5F−2132物質
が500mc g/m1〜62.5mc g/mlの濃
度範囲ではその対数と阻止円径との間は直線関係を示し
、それぞれ21鶴〜12鶴の阻止円を与える。When testing the 5F-2132 substance, Staphylococcus aureus (Staphylococcus aureus) was used.
eus) 209p as the test bacterium.
Use the flat plate method. In this assay, the logarithm of the 5F-2132 substance shows a linear relationship with the diameter of the inhibition circle in the concentration range of 500 mc g/ml to 62.5 mc g/ml, and the inhibition circle of 21 to 12 cranes, respectively. give.
5F−2132物質は、後記する理化学性状を有するの
で、その性状に従って抽出、精製することが可能である
が、以下の方法により効率的に抽出、精製できる。すな
わち、有効成分は主として培養濾液に含まれており、こ
れをダイヤイオンHP−20(三菱化成製)等の多孔性
吸着樹脂に吸着させ、アセトン、メタノール等の水に可
溶性である溶剤と水との混合溶剤で有効成分を溶出する
。この溶出液を減圧濃縮し、これをさらにCM−セファ
デックス(ファルマシア製)、ダイヤイオンHP−20
のカラムクロマトグラフィー等を適宜組み合わせること
によって5F−2132物質を白色無定形粉末として単
離することができる。5F−2132物質は塩基性物質
であるので、遊離塩基あるいは酸付加塩として単離でき
る。5F−2132物質の酸付加塩の例としては、塩酸
、硫酸、硝酸、リン酸、臭化水素酸等のごとき無機酸と
の塩、並びに酢酸。Since the 5F-2132 substance has the physical and chemical properties described below, it can be extracted and purified according to its properties, and can be efficiently extracted and purified by the following method. That is, the active ingredient is mainly contained in the culture filtrate, which is adsorbed onto a porous adsorption resin such as Diaion HP-20 (manufactured by Mitsubishi Kasei), and mixed with water and a water-soluble solvent such as acetone or methanol. The active ingredient is eluted with a mixed solvent. This eluate was concentrated under reduced pressure, and further mixed with CM-Sephadex (manufactured by Pharmacia) and Diaion HP-20.
By appropriately combining column chromatography and the like, 5F-2132 substance can be isolated as a white amorphous powder. Since the 5F-2132 substance is a basic substance, it can be isolated as a free base or an acid addition salt. Examples of acid addition salts of the 5F-2132 material include salts with inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, etc., as well as acetic acid.
クエン酸、酒石酸、安息香酸、アスコルビン酸等のごと
き有機酸との塩が可能であるが、実用として容認される
塩が好ましい。Salts with organic acids such as citric acid, tartaric acid, benzoic acid, ascorbic acid, etc. are possible, but salts that are practically acceptable are preferred.
このようにして得られる抗生物質5F−2132の理化
学性状は次の通りである。The physicochemical properties of the antibiotic 5F-2132 thus obtained are as follows.
(11物質の色と形状:白色粉末
(2)融点:180℃から発泡分解が始まる(3)比旋
光度: 〔α〕グ =−44° (C1,水)(4)分
子量: 400以上1000以下(ゲル濾過法による)
(5) 元素分析: 実測値(%) i C49,
00,H7,21゜N21.09 塩酸塩としての実
測値(%)C42,96,H6,93,N20.1.
(ff19.76上記の元素の他酸素元素(測定せず)
は含まれるが、その他の元素はない。(Color and shape of 11 substances: White powder (2) Melting point: Foaming decomposition begins at 180°C (3) Specific rotation: [α]g = -44° (C1, water) (4) Molecular weight: 400 or more 1000 The following (by gel filtration method) (5) Elemental analysis: Actual value (%) i C49,
00, H7, 21°N21.09 Actual value as hydrochloride (%) C42,96, H6,93, N20.1.
(ff19.76 Oxygen elements other than the above elements (not measured)
is included, but no other elements are present.
(6) 紫外部吸収スペクトル:第1図に示す通りで
ある。2g (E :F、) = 227 n m (
232) 。(6) Ultraviolet absorption spectrum: As shown in FIG. 2g (E:F,) = 227 nm (
232).
λ’By”(E :F、) = 227 n m (2
44) 。λ'By"(E:F,) = 227 nm (2
44).
LINNmllN
λttrx (E:五) = 230Im □l)
(198)。LINNmllN λttrx (E: 5) = 230Im □l)
(198).
(7)赤外部吸収スペクトル:第2図に示す通り335
0、1700 (肩) 、 1640.1530.14
60.1410. 1340゜1240、11?0.1
050.1010. 960. 900.及び860
cm−1に吸収を示す。(7) Infrared absorption spectrum: 335 as shown in Figure 2
0, 1700 (shoulder), 1640.1530.14
60.1410. 1340°1240, 11?0.1
050.1010. 960. 900. and 860
Absorption is shown at cm-1.
(8)核磁気共鳴スペクトル:第3図に示す通りである
。(8) Nuclear magnetic resonance spectrum: As shown in FIG.
(9) 薄層クロマトグラフィー:下記に示す通りη
ある。(9) Thin layer chromatography: η as shown below
be.
シリカゲル60F−254(メルク社製)n−ブタノー
ル−酢酸−水(2: 1 : 1) Rf O,14
n−プロパノ−ルーピリジン−酢酸−水(15:10:
3 :12) Rf O,59クロロホルム−メタ
ノール−4%アンモニア(2:111 上層)Rfo
、35
セルローズF254(メルク社製)
n−ブタノール−酢酸−水(2: 1 : 1) Rf
O,64n−プロパノ−ルーピリジン−酢酸−水(
15:10: 3 :12) Rf O,710I
高圧濾紙電気泳動:高圧濾紙電気泳動装置(サーパン
ト・インスッルメント社製、高圧電源HV5000A、
泳動槽−r−デルLT48A)を用い、東洋濾紙Na5
1(東洋濾紙社製)上で下記の緩衝液を用い、定電圧3
500Vで15分泳動を実施するとき、本物質は陰極に
移動し、アラニンの移動度を1とするとき本物質の移動
度は2.5である。Silica gel 60F-254 (manufactured by Merck) n-butanol-acetic acid-water (2:1:1) Rf O,14
n-propanol-pyridine-acetic acid-water (15:10:
3:12) Rf O, 59 chloroform-methanol-4% ammonia (2:111 upper layer) Rfo
, 35 Cellulose F254 (manufactured by Merck & Co., Ltd.) n-butanol-acetic acid-water (2:1:1) Rf
O,64n-propanol-pyridine-acetic acid-water (
15:10:3:12) Rf O,710I
High-pressure filter paper electrophoresis: High-pressure filter paper electrophoresis device (manufactured by Serpent Instruments, high-voltage power supply HV5000A,
Using an electrophoresis tank (R-Dell LT48A), Toyo Roshi Na5
1 (manufactured by Toyo Roshi Co., Ltd.) using the following buffer solution at a constant voltage of 3.
When electrophoresis is performed at 500 V for 15 minutes, this substance moves to the cathode, and when the mobility of alanine is 1, the mobility of this substance is 2.5.
緩衝液:ピリジン2QQm#と酢酸8mlを全容1I3
Itになるように精製水に溶解したもので、この時の−
は6.4であった。Buffer: Pyridine 2QQm# and acetic acid 8ml total volume 1I3
It is dissolved in purified water so that it becomes It, and at this time -
was 6.4.
(11)アミノ酸組成二本物質を6N Hαで、10
5℃に於て18時間分解f′るとき、ロイシン、セリン
、α、β−ジアミノ酪酸及びβ−アルギニンがそれぞれ
等モル生成する。(11) Amino acid composition Two substances with 6N Hα, 10
When decomposed f' at 5°C for 18 hours, equimolar amounts of leucine, serine, α, β-diaminobutyric acid and β-arginine are produced.
(12)呈色反応:陽性;坂口、ニンヒドリン及びレミ
ニー。(12) Color reaction: positive; Sakaguchi, ninhydrin and Remini.
(13)溶解性:水に易溶、低級アルコール類に難溶、
クロロホルム、n−ヘキサンに不溶。(13) Solubility: Easily soluble in water, poorly soluble in lower alcohols,
Insoluble in chloroform and n-hexane.
5F1132物質の抗菌スペクトルは次表に示す通りで
ある。またマウスを用いた急性毒性試験の結果、200
mg/kg静脈内投与で全鋼生存した。The antibacterial spectrum of the 5F1132 substance is shown in the table below. In addition, as a result of acute toxicity tests using mice, 200
All patients survived when administered mg/kg intravenously.
表S F−2132物質の抗菌スペクトル*β−ラクタ
ム抗生物質高感受性株
(方法) a :アガーごダイリューシ日ン法すニゲロ
ス・グイリューシ日ン法
(培地)l:ハートインヒュージーン寒天培地2ニゲル
コース、どペプトン培地。Table S Antibacterial spectrum of F-2132 substance * β-lactam antibiotic highly sensitive strain (method) a: Agar Godairyushi day method Nigelos Guilyushi day method (medium) l: Heart infugene agar medium 2 Nigel course , peptone medium.
3:ハートインヒュージ日ンプロス培地4:グリセロー
ル・ブイヨン培地
、前記した5F−2132物質の理化学性状、および生
物学的性状と一致する既知抗生物質はなく、本発明の抗
生物質5F−2132物質は新規物質と認め″られた。3: Heart Infuge Nipross medium 4: Glycerol broth medium There is no known antibiotic that matches the physical and chemical properties and biological properties of the 5F-2132 substance described above, and the antibiotic 5F-2132 substance of the present invention is novel. It was recognized as a substance.
5F−2132物質は抗菌活性以外に感染防御作用を有
し、以下に実験結果を示す。The 5F-2132 substance has an anti-infection effect in addition to its antibacterial activity, and the experimental results are shown below.
方法 供試動物;JCL−ICR雄性マウス、4週令。Method Test animal: JCL-ICR male mouse, 4 weeks old.
平均体重21.0 g 、 1群6匹供ge株;シェ
ードモナス・エルギノーザ(Pseudomonas
aeruginosa)E2接種菌液;上記菌株をハ
ート・インヒュージ日ン寒天(Dlf’co社製)平板
に塗抹し、37 ”c 。Average weight 21.0 g, 6 animals per group ge strain; Pseudomonas aeruginosa
aeruginosa) E2 inoculation solution: The above bacterial strain was smeared onto a Heart Infuge Sun Agar (manufactured by Dlf'co) plate at 37"c.
20時間培養後、該菌を集菌し生理食塩水にて所要菌濃
度に希釈し、等量の5%ムチン(Difc。After culturing for 20 hours, the bacteria were collected, diluted with physiological saline to the required bacterial concentration, and added with an equal amount of 5% mucin (Difc).
社製)溶液と混合し接種菌液とした。尚接種容量は0.
5mJ/マウスとした。(manufactured by Seiko Co., Ltd.) solution to obtain an inoculum solution. The inoculation capacity is 0.
It was set as 5mJ/mouse.
試験方法;実施例2で純品として得られたSF−213
2物質を滅菌蒸留水に一定濃度に溶解し、そ(7)0.
2mj!をマウス大腿部皮下に1回投与し、5日後に上
記接種菌液を腹腔内に接種し、4日間マウスの生存を観
察した。Test method: SF-213 obtained as a pure product in Example 2
Dissolve the two substances in sterile distilled water to a certain concentration, and (7) 0.
2mj! was subcutaneously administered once to the thigh of a mouse, and after 5 days, the above-mentioned inoculum solution was intraperitoneally inoculated, and the survival of the mouse was observed for 4 days.
結果を下表に示す通りであった。The results were as shown in the table below.
表(値は1群6匹中の生存数を示す) □ 対照は5F−2132の代りに蒸留水のみを投与した。Table (values indicate the number of survivors out of 6 animals per group) □ For controls, only distilled water was administered instead of 5F-2132.
以上の如<5F−2132物質は明らかに感染防御活性
を示した。As described above, the <5F-2132 substance clearly exhibited infection-preventing activity.
本発明の抗菌性並びに感染防御性を有するSF−213
2物質は注射用蒸留水、生理食塩水等に懸濁して投与す
る。投与形態は皮下注射、静脈、筋肉内注射等の非経口
投与法、又はカプセル等の経口投与法により投与される
。投与量は、動物試験の結果及び種々の状況を勘案して
、総投与量が一定量を越えない範囲で連続的又は間けつ
的に投与する。しかし、その投与量1は、投与方法、患
者の状況、例えば年令2体重、性別、感受性、投与時間
。SF-213 having antibacterial and infection-preventing properties of the present invention
The two substances are administered by suspending them in distilled water for injection, physiological saline, etc. The dosage form is administered parenterally, such as by subcutaneous injection, intravenously, or intramuscularly, or orally, such as by capsule. The dosage should be determined in consideration of the results of animal studies and various circumstances, and the total dosage should be administered continuously or intermittently within a range that does not exceed a certain amount. However, the dosage 1 depends on the administration method, the patient's situation, such as age, weight, sex, sensitivity, and administration time.
併用する薬剤、患者又はその病気の程度に応じて適宜に
変えて投与することは勿論であり、一定の条件の下にお
ける適量と投与回数は上記の指針を基として専門家の適
量決定試験によって決定される。Of course, the administration can be changed as appropriate depending on the concomitant drugs, the patient, and the severity of the disease, and the appropriate dose and frequency of administration under certain conditions are determined by experts' tests to determine the appropriate dose based on the above guidelines. be done.
しかし、一般には1日200〜3000mgの範囲、例
えば、500mgを1〜5回に分けて投与する。However, it is generally administered in a range of 200 to 3000 mg per day, for example 500 mg divided into 1 to 5 doses.
以下に5F−2132物質の製造法の実施中を示すが、
ここに例示しない多くの変形、修飾手段を用い得ること
はもちろんである。The process of manufacturing 5F-2132 substance is shown below.
Of course, many modifications and modification means not exemplified here may be used.
実施例1 (培養) 種菌用培地(グルコース1.0%、殿粉1.0%。Example 1 (culture) Inoculum culture medium (glucose 1.0%, starch 1.0%.
ポリペプトン0.5%、肉エキズ0.2%、酵母エキス
0.3%、大豆粉0.2%、炭酸カルシウム0.2%。Polypeptone 0.5%, meat extract 0.2%, yeast extract 0.3%, soy flour 0.2%, calcium carbonate 0.2%.
pH7,0) 20m 12を100mj?容三角フラ
スコニ分注滅劃り斜面培養から得たノカルディオプシス
・エスピー・5F−2132株(機工研菌寄第6131
号)の菌体を3〜4白金耳接種し、28℃で2日間振盪
培養する。pH7,0) 20m 12 to 100mj? Nocardiopsis sp. 5F-2132 strain obtained from sterile slant culture in an Erlenmeyer flask (Kikoken Bacterial Collection No. 6131
3 to 4 platinum loops of bacterial cells of No.) were inoculated and cultured with shaking at 28°C for 2 days.
コノ種菌5 m /を上記培地80mj!を500 m
1N容三角フラスコに分注滅菌したものに接種し、2
8℃で24時間振盪培養する。この種培養80mj!を
さらに上記培地eoomItを51容三角フラスコに分
注滅菌したもの2本に40m1ずつ接種し、2B’cで
20時間振盪培養する。Kono inoculum 5 m/80 mj of the above medium! 500 m
Dispense into sterilized 1N Erlenmeyer flasks and inoculate 2
Culture with shaking at 8°C for 24 hours. This seed culture is 80mj! Further, the above medium eoomIt was dispensed into two sterilized 51-volume Erlenmeyer flasks, 40 ml each was inoculated, and cultured with shaking at 2B'c for 20 hours.
得られた種培養600mJを20Jの生産培地を含む3
01容ジャーファーメンタ−に接種し、28℃において
通気攪拌(通気20J/min、攪拌350rpm)し
て65時間培養した(ジャーファーメンタ7−2基使用
)。600 mJ of the resulting seed culture containing 20 J of production medium
The seeds were inoculated into a 0.1 volume jar fermenter and cultured at 28°C for 65 hours with aeration (airing 20 J/min, stirring 350 rpm) (using 7-2 jar fermenters).
生産培地の組成は下記の通りである。The composition of the production medium is as follows.
水あめ 4.0%炭酸カル
シウム 0.2%大豆油
0.3%シリコンKM68−2F
0.01%(消泡剤、信越化学製)
大豆粉 2.0%サングレ
イン(サントリー製)0.5%ファーマメディア
1.0%(Traders Oi l
M、i l l製)塩化ニッケル
0.0001%塩化コバルト
0.000f%硫酸第1鉄 0
.001%(pH7,Q滅菌前)
培養終了後、濾過助剤を加え、6N塩酸でpH5に調整
後濾過し、濾液24I!、を得た。Starch syrup 4.0% calcium carbonate 0.2% soybean oil
0.3% silicon KM68-2F
0.01% (antifoaming agent, manufactured by Shin-Etsu Chemical) Soy flour 2.0% Sungrain (manufactured by Suntory) 0.5% Pharmamedia
1.0% (Traders Oil
M, i l l) nickel chloride
0.0001% cobalt chloride
0.000f% ferrous sulfate 0
.. 001% (pH 7, Q before sterilization) After culturing, add a filter aid, adjust the pH to 5 with 6N hydrochloric acid, filter, and filtrate 24I! , obtained.
実施例2
(抽出・精製)
実施例1で得られた培養濾液24ItをダイヤイオンH
P−20(三菱化成製)のカラム2.51に通し、有効
成分を吸着させた。このカラムを水3Itで洗った後、
団%アセトン水で有効成分を溶出した。Example 2 (Extraction/purification) 24It of the culture filtrate obtained in Example 1 was purified by Diaion H.
The active ingredients were adsorbed through column 2.51 of P-20 (manufactured by Mitsubishi Kasei). After washing this column with 3 It of water,
The active ingredient was eluted with % acetone water.
活性区分を合併しく31)、減圧下で濃縮して、アセト
ンを除去し、得ちれた水溶液的21をCM−セファデッ
クスC−25(N、’型)〔ファルマシァ製〕のカラム
150m#に通し、有効成分を吸着させた。このカラム
を水750m1次いで0.05Mの塩化ナトリウム溶液
1500ml!、で洗った後、0.2Mの塩化ナトリウ
ム溶液で溶出し、100mjlずつ分取した。The active fractions were combined (31) and concentrated under reduced pressure to remove acetone, and the resulting aqueous solution of 21 was transferred to a 150 m# column of CM-Sephadex C-25 (N,' type) [manufactured by Pharmacia]. The active ingredients were adsorbed. This column was filled with 750ml of water and then 1500ml of 0.05M sodium chloride solution! , and then eluted with 0.2M sodium chloride solution, and aliquots of 100 mjl were collected.
活性区分(フラクシ日ン隘3〜フラクシ剥ン磁15)を
合併しく1300mjり、これをダイヤイオンHP−2
0のカラム(250m、’)を通して、有効成分を樹脂
に吸着させた。1,300mj of the active section (Fluxy sun 3~Flaxy peeling magnetic 15) was combined and this was made into Diaion HP-2.
The active ingredients were adsorbed onto the resin through a 0 column (250 m,').
カラムを水\150mJで洗った後、6%アセトン水で
溶出した。活性1区分を減圧下に濃縮乾固し、−3F−
2132物質の粗粉末、(淡褐色> 1.76g (純
度:約60%)を得た。After washing the column with 150 mJ of water, it was eluted with 6% acetone water. The active fraction was concentrated to dryness under reduced pressure to obtain -3F-
A crude powder of substance 2132 (light brown color>1.76 g (purity: about 60%) was obtained.
5F−2132物質の純品を得るため、次に上記粗粉末
のうち、800mgを少量の水に溶解し、これをCM−
セラファデックスC−25(Nt型)のカラム(60m
Iりにのせる。ついで水300mJ、0.05Mの塩化
ナトリウム溶液600mA!でカラムを洗った後、0.
2Mの塩化ナトリウム溶液で溶出し、15gずつ分取し
た。フラクシ日ン磁20からフラクシ日ン磁(資)に有
効成分の大部分がまとまるので、この部分を合併し、こ
れをダイヤイオンHP −20のカラム(150m#)
に通し、有効成分を吸着させる。水600mI!、次い
で25%アセトン水] 5Q m j!で展開し15g
ずつ分取する。フラクシ日ン1kllからフラクション
階24(水展開区分)を減圧下に濃縮乾固し、5F−2
132物質の純品を塩酸塩として115mg得た。また
フラクシ日ン隘41からフラクシ日ン11h45(25
%アセトン水展開区分)を減圧下に濃縮乾固し、5F−
2132物質の純品を遊離塩基として247mg得た。In order to obtain a pure substance of 5F-2132, next, 800 mg of the above coarse powder was dissolved in a small amount of water, and this was dissolved in CM-2132.
Ceraphadex C-25 (Nt type) column (60 m
I put it on the rice. Then 300mJ of water and 600mA of 0.05M sodium chloride solution! After washing the column with 0.
Elution was performed with a 2M sodium chloride solution, and 15 g portions were collected. Since most of the active ingredients from Fluxi Nikmagai 20 are collected in Fluxi Nikmagai Co., Ltd., these parts are merged and this is transferred to a column of Diaion HP-20 (150m#).
pass through to absorb the active ingredients. Water 600mI! , then 25% acetone water] 5Q m j! 15g
Separate each portion. Concentrate and dry fraction 24 (water development section) from 1kll of Fraxyi under reduced pressure, and obtain 5F-2.
115 mg of pure substance 132 was obtained as a hydrochloride. Also, from Fraxi Sun 41 to Fraxi Sun 11h45 (25
% acetone water development section) was concentrated to dryness under reduced pressure to obtain 5F-
247 mg of pure substance 2132 was obtained as a free base.
第1図は抗生物質5F−2132の水溶液(実線)。
0、IN塩酸(破線)及び0.IN水酸化ナトリウム溶
液(一点破線)中の紫外部吸収スペクトル、第2図は同
KBr錠での赤外部吸収スペクトル、第■
3図は同D20中、TMSを外部標準としたプロトン核
磁気共鳴スペクトルを示す。Figure 1 shows an aqueous solution of antibiotic 5F-2132 (solid line). 0.IN hydrochloric acid (dashed line) and 0.IN hydrochloric acid (dashed line). Ultraviolet absorption spectrum in IN sodium hydroxide solution (dotted line), Figure 2 is infrared absorption spectrum in KBr tablet, and Figure 3 is proton nuclear magnetic resonance spectrum in D20 using TMS as an external standard. shows.
Claims (1)
生物質5F−2132およびその塩(11物質の色と形
状:白色粉末 (2)融点:180℃から発泡分解が始まる(3)比旋
光度: 〔α):’ =−44° (CI、水)(4
)分子量:400以上1000以下(ゲル濾過法による
) (5)元素分析:実測値(%) i C49,00,
H7,21N21.09 塩酸塩としての実測値(%
)C42,96,H6,93,N20.1.α9.76
上記の元素の他酸素元素(測定せず)は含まれるが、そ
の他の元素はない。 (6)紫外部吸収スペクトル:第1図に示す通りである
。λ”: (E :凡) −227n m (232)
。 λ居(Ei?、) = 227 n m (244)
。 λ’;”’(E :t’m> = 230 n m (
肩)(198)。 (7)赤外部吸収スペクトル:第2図に示す通り335
0、1700 (屑) 、 1640.1530.14
60.1410.1340゜1240、1170.10
50.1010. 960. 900.及び860ロー
1に吸収を示す。 (8)核磁気共鳴スペクトル:第3図に示す通りである
。。 (9) 薄層クロマトグラフィー:下記に示す通りで
ある。 シリカゲル60F−254(メルク社製)n−ブタノー
ル−酢酸−水(2: 1 : 1) Rf O,14
n−プロパノ−ルーピリジン−酢酸−水(15:10:
3 :12) Rf O,59クロロホルム−メタ
ノール−4%アンモニア(2: 1 : 1 上層)
RfO,35セルローズF 254 (メルク社製)n
−ブタノール−酢酸−水(2: 1 : 1) Rf
O,64n−プロパノ−ルーピリジン−酢酸−水(1
5:10: 3712) Rf O,71Ql 高
圧濾紙電気泳動:高圧濾紙電気泳動装置(サーバント・
インスッルメント社製、高圧電源HV500QA、泳動
槽モデルLT48A)を用い、東洋濾紙階51(東洋濾
紙社製)上で下記の緩衝液を用い、定電圧3500Vで
15分泳動を実施するとき、本物質は陰極に移動し、ア
ラニンの移動度を1とするとき本物質の移動度は2.5
である。 緩衝液:ピリジン200mj!と酢酸8mlを全容量3
1になるように精製水に溶解したもので、この時の−は
6.4であった。 (11)アミノ酸組成:本物質を6N Hαで、10
5℃に於て18時間分解するとき、ロイシン。 セリン、α、β−ジアミノMillびβ−アルギニンが
それぞれ等モル生成する。 (12)呈色反応:陽性;坂口、ニンヒドリン及びレミ
ュー。 (13)溶解性:水に5溶、低級アルコール類に難溶、
クロロホルム、n−ヘキサンニ不溶。 2、7カルデイオプシス属に属する抗生物質5F−21
32生産菌を培地中に培養し、培養物に抗生物質5F−
2132を生成蓄積せしめ、これを採取することを特徴
とする新抗生物質5F−2132の製造法。 3、抗生物質5F−2132生産菌がノカルディオプシ
ス・エスピー(Nocardiopsis。 sp、 ) SF 2132である特許請求の範囲第
2項記載の製造法。[Claims] 1. New water-soluble basic antibiotic 5F-2132 and its salts having the following properties as a free base (11 Color and shape of substance: white powder (2) Melting point: foaming decomposition from 180°C Starting (3) Specific rotation: [α):' = -44° (CI, water) (4
) Molecular weight: 400 or more and 1000 or less (by gel filtration method) (5) Elemental analysis: Actual value (%) i C49,00,
H7,21N21.09 Actual value as hydrochloride (%
) C42,96, H6,93, N20.1. α9.76
In addition to the above elements, oxygen element (not measured) is included, but no other elements are present. (6) Ultraviolet absorption spectrum: As shown in FIG. λ”: (E: ordinary) -227 nm (232)
. λ (Ei?,) = 227 nm (244)
. λ';"'(E: t'm> = 230 nm (
shoulder) (198). (7) Infrared absorption spectrum: 335 as shown in Figure 2
0, 1700 (waste), 1640.1530.14
60.1410.1340°1240, 1170.10
50.1010. 960. 900. and 860 row 1 shows absorption. (8) Nuclear magnetic resonance spectrum: As shown in FIG. . (9) Thin layer chromatography: As shown below. Silica gel 60F-254 (manufactured by Merck) n-butanol-acetic acid-water (2:1:1) Rf O,14
n-propanol-pyridine-acetic acid-water (15:10:
3:12) RfO,59 chloroform-methanol-4% ammonia (2:1:1 upper layer)
RfO, 35 Cellulose F 254 (manufactured by Merck) n
-Butanol-acetic acid-water (2:1:1) Rf
O,64n-propanol-pyridine-acetic acid-water (1
5:10: 3712) Rf O, 71Ql High pressure filter paper electrophoresis: High pressure filter paper electrophoresis apparatus (servant
When performing electrophoresis for 15 minutes at a constant voltage of 3500 V using the following buffer on Toyo Roshi Gya 51 (manufactured by Toyo Roshi Co., Ltd.) using a high voltage power supply HV500QA (manufactured by Instrument Co., Ltd., electrophoresis tank model LT48A), The substance moves to the cathode, and when the mobility of alanine is 1, the mobility of this substance is 2.5
It is. Buffer: Pyridine 200mj! and 8 ml of acetic acid to a total volume of 3
It was dissolved in purified water so that the concentration was 1, and - at this time was 6.4. (11) Amino acid composition: This substance in 6N Hα, 10
Leucine when decomposed for 18 hours at 5°C. Equimolar moles of serine, α, β-diamino Mill, and β-arginine are produced. (12) Color reaction: positive; Sakaguchi, ninhydrin and Lemieux. (13) Solubility: 5 soluble in water, slightly soluble in lower alcohols,
Insoluble in chloroform and n-hexane. 2,7 Antibiotic 5F-21 belonging to the genus Caldeiopsis
32-producing bacteria were cultured in a medium, and the culture was treated with antibiotic 5F-
A method for producing a new antibiotic 5F-2132, which comprises producing and accumulating 2132 and collecting it. 3. The manufacturing method according to claim 2, wherein the antibiotic 5F-2132 producing bacterium is Nocardiopsis sp. SF 2132.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP56184643A JPS5886087A (en) | 1981-11-17 | 1981-11-17 | Novel antibiotic substance sf-2132 and its preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP56184643A JPS5886087A (en) | 1981-11-17 | 1981-11-17 | Novel antibiotic substance sf-2132 and its preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5886087A true JPS5886087A (en) | 1983-05-23 |
JPS6250474B2 JPS6250474B2 (en) | 1987-10-24 |
Family
ID=16156815
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP56184643A Granted JPS5886087A (en) | 1981-11-17 | 1981-11-17 | Novel antibiotic substance sf-2132 and its preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS5886087A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0158179A2 (en) * | 1984-04-13 | 1985-10-16 | Kaken Pharmaceutical Co., Ltd. | Antibiotic 6270, process for its production, and its use as an anticoccidiosis agent and a feed additive |
CN110172415A (en) * | 2019-04-23 | 2019-08-27 | 中国极地研究中心 | A kind of arctic nocardia and its tunning optimization method |
-
1981
- 1981-11-17 JP JP56184643A patent/JPS5886087A/en active Granted
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0158179A2 (en) * | 1984-04-13 | 1985-10-16 | Kaken Pharmaceutical Co., Ltd. | Antibiotic 6270, process for its production, and its use as an anticoccidiosis agent and a feed additive |
CN110172415A (en) * | 2019-04-23 | 2019-08-27 | 中国极地研究中心 | A kind of arctic nocardia and its tunning optimization method |
Also Published As
Publication number | Publication date |
---|---|
JPS6250474B2 (en) | 1987-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0352646B1 (en) | Fr901228 substance and preparation thereof | |
EP0182315A2 (en) | Novel antibiotic NK84-0218 pharmaceutical compositions containing it and process for the production of the same | |
GB2084999A (en) | New antibiotic bmg162-af2 a process for production thereof and antitumor drug containing said new antibiotic as active ingredient | |
EP0668358B1 (en) | Antibiotic WAP-8294A, method for preparing the same and antibacterial composition | |
JPS5886087A (en) | Novel antibiotic substance sf-2132 and its preparation | |
JPH03141296A (en) | Fr901375 substance and production thereof | |
EP0144238B1 (en) | A new compound, fr-900451, production and use thereof | |
US4950605A (en) | FR-900493 substance, a process for its production and a pharmaceutical composition containing the same | |
JP3092877B2 (en) | Novel peptides SNA-115 and SNA-115T, method for producing the same, and novel peptide-producing strains | |
JPS60156392A (en) | Fr-900336 substance and its preparation | |
JP2594085B2 (en) | SF2575, a new antitumor antibiotic, and method for producing the same | |
EP0024206A2 (en) | Antitumor substance, composition comprising it and process for preparing said substance | |
JPS6348284A (en) | Novel antibiotic yp-02908l-a and production thereof | |
JP2000086627A (en) | Antibacterial substance be-54476 and its production | |
JPS5811838B2 (en) | Shinko Seibutsutsu BN-165 Shinko Seizouhou | |
JPS63192792A (en) | Novel antibiotic sf 2487 substance and production thereof | |
JP2001046092A (en) | New physiologically active substance nk34944, its production and use thereof | |
JPS5946502B2 (en) | New antibiotic polymyxin T↓1 | |
JPH06343480A (en) | Production of sf 2315a and its pharmacal application | |
JPS6147491A (en) | Antibiotic substance, its preparation, and microorganism | |
JPH1045789A (en) | New physiologically active substance na16887, its production and use thereof | |
JPS6192564A (en) | Microorganism producing novel macrolide antibiotic | |
JPH08176157A (en) | New physiologically active substance epostatin, its production and use | |
JPS60246399A (en) | Novel physiologically active substance foroxymithine, its preparation and use | |
JPS6379585A (en) | Novel microorganism, novel substance ovalicin and production thereof |